Changchun BCHT Biotechnology Co.
Quick facts
Marketed products
- Herpes Zoster Vaccine, Live · Immunology / Infectious Disease
This live attenuated vaccine stimulates the immune system to recognize and respond to varicella-zoster virus, preventing herpes zoster (shingles) reactivation.
Phase 3 pipeline
- DTacP · Oncology
DTacP is a diphtheria toxin-based immunotoxin that targets and eliminates cells expressing specific tumor-associated antigens. - DTacP-IPV/Hib · Immunology / Infectious Disease Prevention
DTacP-IPV/Hib is a combination vaccine that provides immunization against diphtheria, tetanus, acellular pertussis, poliomyelitis, and Haemophilus influenzae type b through inactivated antigens and toxoids. - live attenuated zoster vaccine · Immunology
The live attenuated zoster vaccine works by introducing a weakened form of the varicella-zoster virus to stimulate an immune response.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Changchun BCHT Biotechnology Co. portfolio CI brief
- Changchun BCHT Biotechnology Co. pipeline updates RSS
Frequently asked questions about Changchun BCHT Biotechnology Co.
What are Changchun BCHT Biotechnology Co.'s marketed drugs?
Top marketed products include Herpes Zoster Vaccine, Live.
What is Changchun BCHT Biotechnology Co.'s pipeline?
Changchun BCHT Biotechnology Co. has 3 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include DTacP, DTacP-IPV/Hib, live attenuated zoster vaccine.
Related
- Herpes Zoster Vaccine, Live · Immunology / Infectious Disease
- Sector hub: All tracked pharma companies